A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT ID: NCT03814590
Last Updated: 2022-08-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
1053 participants
INTERVENTIONAL
2019-01-21
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted in 2 parts (Part A and Part B).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
NCT06573281
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
NCT05590403
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
NCT03674177
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
NCT02115815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group Low Dose_PLAIN_A
Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted low dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Group Medium Dose_PLAIN_A
Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group High Dose_PLAIN_A
Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted high dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group Placebo_A
Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Placebo (Saline solution)
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group Low Dose_PLAIN_B
Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted low dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Group Low Dose_AS01E_B
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group Low Dose_AS01B_B
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Group Medium Dose_PLAIN_B
Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group Medium Dose_AS01E_B
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group Medium Dose_AS01B_B
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group High Dose_PLAIN_B
Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted high dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group High Dose_AS01E_B
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Group High Dose_AS01B_B
Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Group Placebo_B
Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
Placebo (Saline solution)
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSV Vaccine (GSK3844766A) unadjuvanted low dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
RSV Vaccine (GSK3844766A) unadjuvanted high dose
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Placebo (Saline solution)
Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written informed consent obtained from the subject prior to performing any study specific procedure.
For Part A:
• A male or female between, and including, 18 and 40 years of age at the time of the first vaccination.
For Part B:
* A male or female between, and including, 60 and 80 years of age at the time of the first vaccination.
* Subjects with residence status allowing free mixing with general community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living.
Exclusion Criteria
* Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the first dose of study vaccine, or planned use during the study period.
* Any medical condition that in the judgment of the investigator would make IM injection unsafe.
* Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone (≥ 20 mg/day, or equivalent). Inhaled and topical steroids are allowed.
* Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 30 days after each study vaccination.
* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
* Hypersensitivity to latex.
* Serious or unstable chronic illness. Patients with chronic stable conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study.
* Any other condition (e.g. chronic obstructive pulmonary disease or severe respiratory condition) that, in the opinion of the investigator, might interfere with the evaluations required by the study.
* History of any neurological disorders or seizures.
* Acute disease and/or fever at the time of enrolment.
* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by the investigator based on medical history, physical examination or laboratory screening tests.
* Hepatomegaly, right upper quadrant abdominal pain or tenderness.
* Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.
* History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
* Previous vaccination with an RSV vaccine.
* Lymphoproliferative disorder and malignancy within 5 years.
* Body mass index \> 40 kg/m².
* Planned move to a location that will prohibit participating in the trial until study end.
* At screening: Hematology parameters (complete blood cell count \[red blood cells, white blood cells\], white blood cells differential count \[lymphocytes, neutrophils and eosinophils\], platelets count or hemoglobin level) and/or biochemistry parameters (creatinine, blood urea nitrogen or liver enzymes \[alanine aminotransferase or aspartate aminotransferase\]) outside the normal laboratory ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator.
For Part A:
* Pregnant or lactating female.
* Female subjects of childbearing potential, except if the subject:
* has practiced adequate contraception for 30 days prior to vaccination, and
* has a negative pregnancy test on the day of vaccination, and
* has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
For Part B:
* Known previous administration of a vaccine containing MPL, QS-21 and/or MF59 (e.g. GSK Biologicals' vaccine against human papillomavirus infection marketed as Cervarix, GSK Biologicals' Herpes Zoster vaccine marketed as Shingrix, an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine \[HZ/su\], or MF59 adjuvanted influenza vaccines \[e.g. Fluad\]).
* Planned administration of GSK Biologicals' Herpes Zoster vaccine marketed as Shingrix or an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine \[HZ/su\] within 180 days after the second dose of the study vaccine.
* Bedridden subjects.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Stockbridge, Georgia, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Elkridge, Maryland, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Hickory, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Mt. Pleasant, South Carolina, United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Wilrijk, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrom V. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-000849-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
208851
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.